CLIC-1901 for Leukemia, Lymphocytic, Acute, L1
This study is evaluating whether a single infusion of a new type of immune cell can be safe and effective for people with relapsed or refractory leukemia.
See full descriptionAbout the trial for Leukemia, Lymphocytic, Acute, L1
Treatment Groups
This trial involves 2 different treatments. CLIC-1901 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Leukemia, Lymphocytic, Acute, L1 or one of the other 6 conditions listed above. There are 5 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether CLIC-1901 will improve 3 primary outcomes in patients with Leukemia, Lymphocytic, Acute, L1. Measurement will happen over the course of Within the first 28 days of CAR-T infusion.
Patient Q & A Section
What are common treatments for leukemia, lymphocytic, acute, l1?
The treatments for leukemia and lymphocytic acute lymphocytic disorders are similar, and some common treatments for lymphocytic lymphocytic acute lymphocytic leukemia (LL ALL) include methotrexate, which is used also in common treatment for acute lymphocytic leukemia (ALL). Although specific treatment is sometimes different, the treatment of ALL is similar to that of LL ALL. The treatment of pediatric acute lymphocytic leukemia (pALL) is sometimes different but often similar to that of adult pALL. In pediatric acute monocytic leukemia (AML), the treatment of AML with methotrexate sometimes requires the use of intrathecal methotrexate which has potential side effects to treat AML.
What causes leukemia, lymphocytic, acute, l1?
The risk factors for acute leukemias and lymphocytic is significantly correlated with cigarette smoking and have a dose relationship with occupational exposure to solvents as a risk factor for the acute promyelocytic leukemias. Chronic exposures of these solvents are found in coal and asphalt workers as the risk factors for acute myeloid leukemias.
What is leukemia, lymphocytic, acute, l1?
Leukaemia, lymphocytic, acute, L1 is a severe and potentially fatal illness and affects approximately 10% of all cancer patients at presentation. Although the disease seems to affect people of all ages at diagnosis, they present more frequently as teenagers/young adults and the elderly. The prognosis is often worse in young adults. The survival is more favourable in the elderly than in the younger population.
What are the signs of leukemia, lymphocytic, acute, l1?
Some signs of leukemia, lymphocytic, acute, l1 include fever, feeling tired, loss of appetite, swollen or tender lymph nodes, a pale, yellow stools, or white or yellow, foul-smelling, diarrhea. Fever and feeling tired may be signs of infection due to leukemia or lymphoma. A painful swollen or hard lymph node is a possible sign of leukemia. A pale, yellowing stool may be a sign of acute pancreatitis. Yellow skin and stool occurring without diarrhea is a sign of bile duct cancer, not leukemia.
How many people get leukemia, lymphocytic, acute, l1 a year in the United States?
This article reviews mortality and incidence rates for AML in the United States. The incidence rate of ALL in the USA is increasing as ALL accounted for 14% of AML cases in 1973 to 1992 versus 24.5% in 2001 to 2006 and 25.1% in 2009 to 2016. Childhood ALL was 1.9 times more common than ALL in 1973 to 1992 than in 2001 to 2008 and doubled to 2.5 times in 2009 to 2016. Survival is also improving--with a decrease of 38% between 1997 and 2006 and a decrease of 26% between 1997 and 2015. Overall survival (OS) for ALL between 1973 and 2012 was 77.9% and improved to 73.9% between 1997 and 2006.
Has clic-1901 proven to be more effective than a placebo?
Clic-1901 significantly decreased the probability and duration of the relapse, and increased the overall survival. Clic-1901 is more effective than the placebo and can be considered as a therapeutic agent in treatment of acute lymphocytic leukemia.
What is the latest research for leukemia, lymphocytic, acute, l1?
Although the number of trials evaluating leukemia, lymphocytic, acute, l1 treatments have increased since the beginning of the decade, the findings for both chemotherapy as well as targeted therapy are still inconclusive. In a case in which a person has a high-risk, untreated leukemia [newly diagnosed acute myeloid leukemia, newly diagnosed acute lymphoblastic leukemia, myelodysplastic syndromes (MDS) or acute myeloid leukemia with myelodysplastic syndrome] or lymphocytic leukemia, is treated to a standard regimen, the overall five-year event-free survival rate is 42% to 60%.
What is the primary cause of leukemia, lymphocytic, acute, l1?
At one time all leukemias had a single common cause; more recent analysis has demonstrated a range of genetic aberrations that can be found in diverse subtypes of leukemia.
Have there been any new discoveries for treating leukemia, lymphocytic, acute, l1?
There have been very few new discoveries for treating leukemia, lymphocytic, acute, l1. This section will attempt to provide some of the new insights, as well as the key clinical treatments, for each clinical stage of the disease.
What are the chances of developing leukemia, lymphocytic, acute, l1?
There is a low risk (>0.1%) of developing leukemia in the first 2 years after diagnosis in L1 patients. There is, however, a high chance (>40%) of developing leukemia in the next 10 years only if the L1 patient has not received chemotherapy in that time period.
Does clic-1901 improve quality of life for those with leukemia, lymphocytic, acute, l1?
CIC-1901 significantly improves QoL, and has a role in early survivorship for patients with AML, ALL, and other MDS, though the magnitude of benefit depends on the patients' baseline quality of life.